Phase 3 Recruiting Academic/Other
This phase III trial compares stereotactic body radiation therapy (SBRT), (five treatments over two weeks using a higher dose per treatment) to usual radiation therapy (20 to 45 treatments over 4 to 9 weeks) for the treatment of high-risk …
Sponsor: NRG Oncology
NCT ID: NCT05946213
Sites in Illinois: - Alton Memorial Hospital — Alton, Illinois
- Advocate Outpatient Center - Aurora — Aurora, Illinois
- Advocate Good Shepherd Hospital — Barrington, Illinois
- Illinois CancerCare-Bloomington — Bloomington, Illinois
- Illinois CancerCare-Carthage — Carthage, Illinois
Phase 3 Recruiting Network
This study is being done to answer the following question: can the chance of prostate cancer growing or spreading be lowered by adding a drug to the usual combination of drugs? This study would like to find out if this approach is better o…
Sponsor: Canadian Cancer Trials Group
NCT ID: NCT06592924
Sites in Illinois: - University of Illinois — Chicago, Illinois
- Elmhurst Memorial Hospital — Elmhurst, Illinois
- Edward Hospital/Cancer Center — Naperville, Illinois
- Edward Hospital/Cancer Center?Plainfield — Plainfield, Illinois
- Memorial Hospital East — Shiloh, Illinois
Phase 3 Recruiting Network
This phase III trial tests two questions by two separate comparisons of therapies. The first question is whether enhanced therapy (apalutamide in combination with abiraterone + prednisone) added to standard of care (prostate radiation ther…
Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT04423211
Sites in Illinois: - Alton Memorial Hospital — Alton, Illinois
- OSF Saint Anthony's Health Center — Alton, Illinois
- Rush-Copley Medical Center — Aurora, Illinois
- Illinois CancerCare-Bloomington — Bloomington, Illinois
- Illinois CancerCare-Canton — Canton, Illinois
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of adding docetaxel to hormonal therapy and apalutamide versus hormonal therapy and apalutamide alone in treating patients with prostate cancer that has spread from where it first started (primary s…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06931340
Sites in Illinois: - Illinois CancerCare-Bloomington — Bloomington, Illinois
- Illinois CancerCare-Canton — Canton, Illinois
- Illinois CancerCare-Carthage — Carthage, Illinois
- Centralia Oncology Clinic — Centralia, Illinois
- Rush MD Anderson Cancer Center — Chicago, Illinois
Phase 3 Recruiting Industry
This study will explore whether a combination of the investigational drug mevrometostat (PF-06821497) and enzalutamide will work better than taking enzalutamide alone in participants with mCSPC who are ARPI naïve and have not yet received …
Sponsor: Pfizer
NCT ID: NCT07028853
Sites in Illinois: - Associated Urological Specialists - Chicago Ridge — Chicago Ridge, Illinois
- Cancer Care Specialists of Illinois — Decatur, Illinois
- Cancer Care Specialists of Illinois — O'Fallon, Illinois
Phase 3 Recruiting Industry
The purpose of this study is to assess the efficacy and safety of opevesostat plus daily corticosteroids compared to alternative abiraterone acetate or enzalutamide in participants with Metastatic Castration-resistant Prostate Cancer (mCRP…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06136650
Sites in Illinois: - Edward-Elmhurst Healthcare, Elmhurst Hospital-Nancy W. Knowles Cancer Center ( Site 0074) — Elmhurst, Illinois
- Edward-Elmhurst Healthcare, Edward Hospital-Edward Cancer Center ( Site 0075) — Naperville, Illinois
- Illinois Cancer Care ( Site 0104) — Peoria, Illinois
Phase 3 Recruiting Industry
This is a phase 3, randomized, open-label study of opevesostat compared to alternative abiraterone acetate or enzalutamide in participants with metastatic castration-resistant prostate cancer (mCRPC) with respect to overall survival (OS) i…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06136624
Sites in Illinois: - University of Illinois at Chicago ( Site 0105) — Chicago, Illinois
- University of Chicago Medical Center ( Site 0045) — Chicago, Illinois
Phase 3 Recruiting Industry
This is a prospective, open-label Phase 3 study to evaluate copper Cu 64 PSMA I\&T injection for PET/CT imaging in patients with newly diagnosed unfavorable intermediate high-risk, high-risk or very high-risk prostate cancer.
Sponsor: Curium US LLC
NCT ID: NCT06235151
Sites in Illinois: - Edward Hines Jr. VA Hospital — Hines, Illinois
Phase 3 Recruiting Industry
This study will explore whether a combination of the investigational drug PF-06821497 and enzalutamide will work better than taking enzalutamide alone in participants with mCRPC who are ARSi or abiraterone naïve.
Sponsor: Pfizer
NCT ID: NCT06629779
Sites in Illinois: - Accellacare of Duly — Lisle, Illinois
- Duly Health and Care (Bone Scintigraphy) — Lisle, Illinois
- Blessing Hospital — Quincy, Illinois
- Blessing Physician Services — Quincy, Illinois
- Duly Health and Care (CT and MRI) — Westmont, Illinois
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of lutetium (177Lu) vipivotide tetraxetan (AAA617) in participants with oligometastatic prostate cancer (OMPC) progressing after definitive therapy to their primary tumor. Th…
Sponsor: Novartis Pharmaceuticals
NCT ID: NCT05939414
Sites in Illinois: - University of Chicago — Chicago, Illinois
- The Cancer Institute of Alexian Brothers — Elk Grove, Illinois
Phase 3 Recruiting Industry
The aim for this study is to assess the diagnostic performance of 64Cu-SAR-bisPSMA PET to detect regional nodal metastases.
Sponsor: Clarity Pharmaceuticals Ltd
NCT ID: NCT06056830
Sites in Illinois: - NorthShore University Health System, Glenbrook Hospital — Glenview, Illinois
Phase 3 Recruiting Industry
The intention of the study is to demonstrate superiority of AZD2265 relative to standard of care treatments by assessment of radiographic progression-free survival (rPFS) and overall survival (OS) in participants with mCRPC.
Sponsor: AstraZeneca
NCT ID: NCT07611110
Sites in Illinois: - Research Site — O'Fallon, Illinois
Phase 3 Recruiting Industry
This is an open label, longitudinal Phase 3 study of prostate specific membrane antigen (PSMA) positron emission tomography (PET) combined with magnetic resonance imaging (MRI) compared to standard of care (SOC) for the detection of prosta…
Sponsor: Telix Pharmaceuticals (Innovations) Pty Limited
NCT ID: NCT07052214
Sites in Illinois: - UroPartners,LLC — Chicago, Illinois
Phase 3 Recruiting Industry
This study will test whether BNT324 is safe and works better against metastatic castration-resistant prostate cancer (mCRPC) than the current standard of care (SoC) chemotherapy, which is docetaxel (given together with the steroid medicine…
Sponsor: BioNTech SE
NCT ID: NCT07365995
Sites in Illinois: - Illinois Cancer Specialists — Niles, Illinois
- Illinois CancerCare PC — Peoria, Illinois
Phase 2 Recruiting NIH
This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other places in the…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT03866382
Sites in Illinois: - OSF Saint Anthony's Health Center — Alton, Illinois
- Rush-Copley Medical Center — Aurora, Illinois
- Illinois CancerCare-Bloomington — Bloomington, Illinois
- Loyola Center for Health at Burr Ridge — Burr Ridge, Illinois
- Illinois CancerCare-Canton — Canton, Illinois
Phase 2 Recruiting Network
This phase II trial tests how well carboplatin before surgery works in treating patients with high-risk prostate cancer and an inherited BRCA1 or BRCA2 gene mutation. Carboplatin is in a class of medications known as platinum-containing co…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05806515
Sites in Illinois: - NorthShore University HealthSystem-Evanston Hospital — Evanston, Illinois
- NorthShore University HealthSystem-Glenbrook Hospital — Glenview, Illinois
- NorthShore University HealthSystem-Highland Park Hospital — Highland Park, Illinois
- North Shore Medical Center — Skokie, Illinois
Phase 2 Recruiting Academic/Other
This phase II trial evaluates whether genetic testing in prostate cancer is helpful in deciding which study treatment patients are assigned. Patient cancer tissue samples are obtained from a previous surgery or biopsy procedure and tested …
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06632977
Sites in Illinois: - Illinois CancerCare-Bloomington — Bloomington, Illinois
- Illinois CancerCare-Canton — Canton, Illinois
- Carle at The Riverfront — Danville, Illinois
- Carle Physician Group-Effingham — Effingham, Illinois
- Illinois CancerCare-Eureka — Eureka, Illinois
Phase 2 Recruiting Industry
The purpose of this study is to collect long term safety data in subjects who are continuing to derive clinical benefit from treatment with Enzalutamide from the subjects participation in an enzalutamide clinical study sponsored by Astella…
Sponsor: Astellas Pharma Global Development, Inc.
NCT ID: NCT02960022
Sites in Illinois: - Site US10002 — Chicago, Illinois
- Springfield Clinic, LLP — Springfield, Illinois
Phase 2 Recruiting Industry
A multicenter, open-label, prospective study to investigate immune boost response changes in patients with metastatic castrate-resistant prostate cancer (mCRPC).
Sponsor: Dendreon
NCT ID: NCT06134232
Sites in Illinois: - Associated Urological Specialists — Chicago Ridge, Illinois
- UroPartners — Glenview, Illinois
- Advanced Urology Associates — New Lenox, Illinois
Phase 2 Recruiting Federal
This is an unblinded, randomized clinical study comparing the efficacy of DNA damaging chemotherapy using carboplatin, to standard of care therapy for patients who have metastatic castrate resistant prostate cancer. This trial will use ola…
Sponsor: VA Office of Research and Development
NCT ID: NCT04038502
Sites in Illinois: - Jesse Brown VA Medical Center, Chicago, IL — Chicago, Illinois
Phase 1, Phase 2 Recruiting Industry
This is a dose-finding study to assess the safety and preliminary antitumor activity of Pocenbrodib alone or with darolutamide in patients with metastatic castration-resistant prostate cancer (mCRPC)
Sponsor: Pathos AI, Inc.
NCT ID: NCT06785636
Sites in Illinois: - University of Chicago — Chicago, Illinois
Phase 2 Recruiting NIH
This phase II trial studies how well lutetium Lu 177 dotatate works in treating patients with prostate cancer with neuroendocrine differentiation that has spread to other places in the body (metastatic). Neuroendocrine differentiation refe…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05691465
Sites in Illinois: - Northwestern University — Chicago, Illinois
Phase 2 Recruiting Academic/Other
This phase II trial compares the effect of FDG-positron emission tomography (PET)-guided metastasis directed radiation therapy (MDRT) in combination with standard treatments to standard treatments alone in treating patients with prostate c…
Sponsor: Northwestern University
NCT ID: NCT06244004
Sites in Illinois: - Northwestern University — Chicago, Illinois
- Northwestern Medicine: Kishwaukee — DeKalb, Illinois
- Northwestern Medicine: Delnor — Geneva, Illinois
- Northwestern University Oak Brook IL453 — Oak Brook, Illinois
- Northwestern Medicine Orland Park — Orland Park, Illinois
Phase 2 Recruiting NIH
This phase II randomized control trial assesses the effect of Urolithin A (Uro-A) supplementation compared to placebo in men with biopsy-confirmed prostate cancer undergoing radical prostatectomy (RP) progressive disease. A total of 90 men…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06022822
Sites in Illinois: - Northwestern University — Chicago, Illinois
- University of Chicago Comprehensive Cancer Center — Chicago, Illinois
Phase 1, Phase 2 Recruiting Academic/Other
This phase I/II tests the safety, side effects and best dose of ruxolitinib in combination with enzalutamide and how well it works in treating patients with prostate cancer that remains despite blocking hormone production (castration-resis…
Sponsor: University of Michigan Rogel Cancer Center
NCT ID: NCT06616155
Sites in Illinois: - Rush University — Chicago, Illinois